<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555487</url>
  </required_header>
  <id_info>
    <org_study_id>201411046MINB</org_study_id>
    <nct_id>NCT03555487</nct_id>
  </id_info>
  <brief_title>Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan.</brief_title>
  <acronym>parathyroid</acronym>
  <official_title>Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aims to&#xD;
&#xD;
      1. compare the detection rates among sonography, MIBI scan and 18F-FCH PET for localization&#xD;
      of the parathyroid lesions including adenoma, hyperplasia or carcinoma; evaluate the&#xD;
      usefulness of 18F-FCH PET as a second-line tracer in MIBI scan negative patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperparathyroidism is a common endocrine disorder. Primary hyperparathyroidism is due to&#xD;
      over-secretion of parathyroid hormone and subsequently hypercalcemia, phyophosphatemia and&#xD;
      osteoporosis, while secondary hyperparathyroidism is due to physiological secretion of&#xD;
      parathyroid hormone by the parathyroid glands in response to hypocalcemia. Surgical approach&#xD;
      is the major treatment modality for majority of these patients with hyperparathyroidism.&#xD;
      Pre-operative localization of hyperfunctioning glands may lead to minimally invasive surgery.&#xD;
      The most commonly used imaging modality for this purpose is 99mTc-sestaMIBI, and supplemented&#xD;
      by ultrasonography of the neck. However, the sensitivity and specificity is significantly&#xD;
      lower in patients with multiple parathyroid lesions.&#xD;
&#xD;
      Recently, some investigators reported cases of parathyroid adenoma discovered incidentally on&#xD;
      choline PET images performed for prostate cancer. 11C or 18F choline is a PET probe used in&#xD;
      imaging prostate cancer and hepatocellular carcinoma. As a phospholipid analog, choline is&#xD;
      integrated into newly synthesized membranes of proliferating cells by up-regulation of&#xD;
      choline kinase. In addition, a previous study showed that the activity of&#xD;
      phospholipid/Ca2+-dependent protein kinase was also higher in hyper-functioning parathyroid&#xD;
      tissue than in atrophic parathyroid gland. Both mechanisms may be responsible for the uptake&#xD;
      of choline tracers in hyperfunctioning parathyroid tissue. Up to now, there are only 3&#xD;
      original reports with limited patients using choline PET in the evaluation of&#xD;
      hyperparathyroidism.&#xD;
&#xD;
      This prospective study aims to&#xD;
&#xD;
        1. compare the detection rates among sonography, MIBI scan and 18F-FCH PET for localization&#xD;
           of the parathyroid lesions including adenoma, hyperplasia or carcinoma;&#xD;
&#xD;
        2. evaluate the usefulness of 18F-FCH PET as a second-line tracer in MIBI scan negative&#xD;
           patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2015</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET imaging</measure>
    <time_frame>in 3 days</time_frame>
    <description>By visual interpretation if there are focal areas of abnormal 18F-FCH accumulation. The presence, number, size, character, and location of suspected lesions will be filed for each patient in this study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Parathyroid Diseases</condition>
  <arm_group>
    <arm_group_label>18F-choline PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-choline PET</intervention_name>
    <description>5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.</description>
    <arm_group_label>18F-choline PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parahyperthyroidism (serum iPTH 65 pg / mL; normal range : 12-65), merged with normal&#xD;
             or high serum calcium concentration (serum calcium 2.35 mmol / L; normal range:&#xD;
             2.15-2.58) and normal or low serum phosphate concentration (serum phosphorus 3.75 mg /&#xD;
             dL; normal range : 2.5-5.0).&#xD;
&#xD;
          -  High serum calcium concentration (serum calcium 2.58 mmol/L), but the blood&#xD;
             parathyroid hormone concentration in normal range (serum iPTH 12-65pg / mL),&#xD;
             hyperthyroidism is suspected.&#xD;
&#xD;
          -  MIBI scan has been performed or arranged.&#xD;
&#xD;
          -  Age：above 20 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with Familial hypocalciuric hypercalcemia：daily calcium excretion &lt; 100 mg/24h&#xD;
             and fractional excretion of calcium &lt; 1%.&#xD;
&#xD;
          -  taking or was taking lithium.&#xD;
&#xD;
          -  vitamin D deficiency (25-OH vitamin D &lt; 10 ng/mL).&#xD;
&#xD;
          -  Patients with pregnancy or recently having a plan for pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan Univeristy Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>18F choline</keyword>
  <keyword>PET</keyword>
  <keyword>Tc-99m sestaMIBI</keyword>
  <keyword>SPECT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parathyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

